Antiplatelet Drugs: A Journey from Bench to Bedside

The story of antiplatelet drugs begins not in a pharmacy, but in the laboratory of an Italian scientist. In 1882, Giulio Bizzozero first recognized that blood platelets aggregate at sites of vascular injury, forming haemostatic plugs that arrest bleeding ahead of plasma coagulation. This dual nature of platelets — physiologically life-saving, pathologically life-threatening — would define decades of research. Platelet aggregation within intact vessels, particularly over ruptured atherosclerotic plaques, drives the formation of arterial thrombi responsible for myocardial infarction and ischaemic stroke. The challenge for pharmacology has always been the same: the mechanism of beneficial haemostasis and lethal thrombosis is identical, so therapeutic intervention must exploit differences in pathophysiological context rather than the aggregation process itself.

Despite Bizzozero's discovery, meaningful investigation of platelet aggregation stalled for nearly eighty years. The breakthrough came in 1962 when Gustav Born, drawing inspiration from turbidimetric measurements he had conducted during his Oxford doctoral work, developed optical aggregometry. The technique is elegantly simple: as platelets aggregate in platelet-rich plasma, light transmission through the sample increases. The method was reproducible, quantifiable, and adaptable to a wide range of experimental conditions. The original papers in Nature and the Journal of Physiology became Citation Classics, cited thousands of times and still foundational to platelet research today.

Optical aggregometry immediately began yielding new knowledge. Born and Cross characterized aggregation kinetics with respect to velocity, temperature, and pH. They identified two essential cofactors: calcium and fibrinogen. Born proposed in 1965 that fibrinogen forms molecular "bridges" between adjacent platelets — a hypothesis confirmed electron-microscopically a decade later. Platelet shape change, the first visible sign of activation, was shown to follow Michaelis-Menten kinetics, suggesting that agonists such as ADP bind to specific membrane receptors.

The technique also enabled discovery of the first aggregation inhibitors. ATP and adenosine were tested initially because of their structural similarity to the proaggregatory ADP. ATP competitively inhibited aggregation; adenosine was more potent. 2-substituted adenosine derivatives, particularly 2-chloroadenosine, proved most effective. Early human volunteer experiments — described by the authors as experiments "which could conceivably have been harmful and which would now be strictly forbidden" — demonstrated that the relative potency of adenosine analogues as aggregation inhibitors matched their potency as vasodilators, a relationship later explained by the shared cyclic AMP signalling pathway in platelets and vascular smooth muscle.

By 1964, aggregation inhibitors had been shown to prevent thrombus formation in vivo. The closing lines of Born's landmark 1962 Nature paper had already articulated the therapeutic vision: if ADP participates in vascular platelet aggregation, some related substance might be used to inhibit thrombosis. That prediction proved remarkably accurate. Yet despite these foundations being laid by 1965, more than two decades would pass before the first antiplatelet drug entered clinical practice.

Aspirin's effects on platelets were noted before their explanation. By the late 1960s, researchers had demonstrated that aspirin — but not its metabolite sodium salicylate — prolonged bleeding time, inhibited platelet aggregation, and blocked ADP release from platelets. What was missing was a mechanism.

In 1971, Bryan Smith and Jim Willis, working in London with Born and Sir John Vane respectively, reported that aspirin selectively inhibited the release of prostaglandin E₂-like activity from platelets, suggesting it blocked the conversion of arachidonic acid into prostaglandins. This was published alongside Vane's landmark paper on prostaglandin synthesis inhibition as the shared mechanism of aspirin-like drugs. Still, no direct link between prostaglandin synthesis and platelet aggregation was apparent — the two prostaglandins known at the time had no obvious platelet effects.

That link was provided by Nobel Laureate Bengt Samuelsson and colleagues at the Karolinska Institutet between 1973 and 1975. They elucidated platelet arachidonic acid metabolism, identifying unstable cyclic endoperoxides (PGG₂ and PGH₂) and trapping an extremely potent, short-lived platelet-aggregating prostanoid: thromboxane A₂ (TXA₂). TXA₂ was activated by platelet agonists and blocked by aspirin, providing the missing biochemical link. Gerry Roth and Phil Majerus at Washington University then confirmed the molecular mechanism: aspirin acetylates and irreversibly inactivates prostaglandin synthase (PGH-synthase) by blocking the cyclooxygenase (COX) channel via acetylation of a strategically located serine residue — Ser-529 in COX-1 and Ser-516 in COX-2.

One year later came a complication. Moncada and colleagues discovered prostacyclin (PGI₂), a vessel-wall prostanoid with potent vasodilatory and platelet-inhibitory properties whose synthesis aspirin also inhibits. This created the so-called "aspirin dilemma": simultaneous suppression of both platelet TXA₂ (prothrombotic) and vascular PGI₂ (antithrombotic). The concern that higher aspirin doses might blunt their own benefit by suppressing PGI₂ drove a worldwide search for the lowest effective dose.

Researchers in Rome, Nashville, and Dublin demonstrated through meticulous biochemical dose-finding that 30 mg of aspirin daily could almost completely abolish platelet COX-1 activity while leaving vascular prostacyclin largely intact — exploiting the cumulative, irreversible nature of platelet COX-1 acetylation over repeated daily doses. Platelets, lacking nuclei, cannot replenish COX-1 once inactivated. This "hit-and-run" pharmacodynamics justifies once-daily dosing despite aspirin's short plasma half-life. The ISIS-2 trial in 1988, testing 160 mg daily in 17,187 patients with acute myocardial infarction, confirmed a significant reduction in vascular mortality, marking the transition from empirical observation to rationally designed clinical pharmacology.

Dipyridamole, synthesized in the 1950s and introduced as a coronary vasodilator in the early 1960s, was found to inhibit platelet adhesiveness and reduce experimental thrombosis. Its antiplatelet mechanism involves potentiating the inhibitory effect of adenosine by blocking its uptake into platelets — a discovery that unexpectedly opened research into trypanocidal drug development, since trypanosomes similarly rely on adenosine uptake. Reformulated for improved bioavailability, dipyridamole was shown in the ESPS-2 trial to reduce stroke in cerebrovascular disease, with additive benefit when combined with aspirin.

Ticlopidine, synthesized in 1972, was discovered through in vivo phenotypic screening — a fortunate circumstance, since it is inactive in vitro and requires hepatic conversion to an active metabolite. That metabolite blocks the platelet P2Y₁₂ ADP receptor, a target not identified until over twenty years after the drug's synthesis. The structurally related clopidogrel followed, with a superior safety profile. Like aspirin, clopidogrel causes cumulative, irreversible inhibition of platelet function; platelet function returns to normal approximately seven days after stopping either drug. The P2Y₁₂ receptor is now the target for newer reversible antagonists.

Since TXA₂ and ADP represent only two of multiple pathways converging on platelet aggregation, blocking either one leaves substantial residual activity. Recognising that the activated GPIIb/IIIa receptor — the integrin αIIbβ3 — represents the final common pathway regardless of agonist, Barry Coller at the State University of New York developed monoclonal antibodies against it. His antibody 10E5 abolished aggregation in response to all tested agonists and could induce a functional thrombasthenic phenotype in normal platelets, mirroring the inherited condition Glanzmann thrombasthenia first described in 1918.

A humanised chimeric antibody, abciximab, was developed for clinical use and approved in 1994 for patients undergoing percutaneous coronary intervention. However, oral GPIIb/IIIa antagonists evaluated in over 40,000 patients across five large trials failed to outperform aspirin and may have increased mortality — possibly because partial receptor blockade paradoxically activates rather than inhibits the receptor, and because inadequate dose-finding preceded large-scale trials.

The development of antiplatelet therapy spans more than a century of scientific discovery, from Bizzozero's microscope to molecular crystallography. The story is one of serendipity, interdisciplinary collaboration, and the steady translation of basic science into clinical benefit. Aspirin, dipyridamole, the thienopyridines, and parenteral GPIIb/IIIa antagonists each emerged from distinct historical threads that converged on a common pharmacological goal: interrupting arterial thrombosis without abolishing the haemostasis essential to life.